Skip to content

Comparative study on the efficacy of prolide, miguda and domestic zoledronic acid in the treatment of osteoporosis patients with type 2 diabetes mellitus

Comparative study on the efficacy of prolide, miguda and domestic zoledronic acid in the treatment of osteoporosis patients with type 2 diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104654
Enrollment
Unknown
Registered
2025-06-20
Start date
2025-06-30
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis, type 2 diabetes

Interventions

Prolide group:NA
Miguda group:NA
Domestic zoledronic acid group:NA

Sponsors

The First People’s Hospital of Longquanyi District Chengdu, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The age ranged from 50 to 70 years old, regardless of gender; 2. Type 2 diabetes mellitus; 3. It meets the diagnostic criteria for osteoporosis in the guidelines for the diagnosis and treatment of primary osteoporosis, that is, it meets at least one of the following three criteria: (1) The T value of the bone mineral density of the axial bone (lumbar spine 1-4, femoral neck or total hip) or 1/3 of the distal radius measured by DXA is = 3 months).

Exclusion criteria

Exclusion criteria: 1. Combined with other diseases that seriously affect bone metabolism, such as hyperparathyroidism or hypothyroidism, hyperthyroidism or hypothyroidism; 2. Patients with severe heart, liver and lung dysfunction; 3. Renal function impairment (estimated glomerular filtration rate = 35ml/min/1.73^2).

Design outcomes

Primary

MeasureTime frame
bone mineral density;

Secondary

MeasureTime frame
Bone metabolism markers;

Countries

China

Contacts

Public ContactJixiang Ying

The First People’s Hospital of Longquanyi District Chengdu, China

810438897@qq.com+86 135 4128 4949

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026